Cargando…
Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis
The recent guidelines on the Programmatic Management of Drug-Resistant Tuberculosis (DR-TB) in India (PMDT) have been released in March 2021 on World TB Day. The new guidelines have considered emerging diagnostic trends including TrueNat, Xpert Mtb/XDR, Next generation sequencing and evaluation for...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tuberculosis Association of India. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366038/ https://www.ncbi.nlm.nih.gov/pubmed/35760475 http://dx.doi.org/10.1016/j.ijtb.2021.08.013 |
_version_ | 1783738828539822080 |
---|---|
author | Gupta, Mansi Ish, Pranav Malhotra, Nipun |
author_facet | Gupta, Mansi Ish, Pranav Malhotra, Nipun |
author_sort | Gupta, Mansi |
collection | PubMed |
description | The recent guidelines on the Programmatic Management of Drug-Resistant Tuberculosis (DR-TB) in India (PMDT) have been released in March 2021 on World TB Day. The new guidelines have considered emerging diagnostic trends including TrueNat, Xpert Mtb/XDR, Next generation sequencing and evaluation for resistance to newer drugs including Bedaquiline (Bdq) and Delamanid. The emerging therapeutic trends include focus on oral shorter Bdq based regimen with phasing out injectables use. The replacement sequence of drugs for DR-TB have also been updated. Updated definitions for pre-XDR, XDR, culture conversion and default have also been added. These guidelines are a paradigm shift which will make treating DR-TB easier and more efficient especially during the ongoing COVID-19 pandemic crisis. |
format | Online Article Text |
id | pubmed-8366038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Tuberculosis Association of India. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83660382021-08-16 Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis Gupta, Mansi Ish, Pranav Malhotra, Nipun Indian J Tuberc Viewpoint The recent guidelines on the Programmatic Management of Drug-Resistant Tuberculosis (DR-TB) in India (PMDT) have been released in March 2021 on World TB Day. The new guidelines have considered emerging diagnostic trends including TrueNat, Xpert Mtb/XDR, Next generation sequencing and evaluation for resistance to newer drugs including Bedaquiline (Bdq) and Delamanid. The emerging therapeutic trends include focus on oral shorter Bdq based regimen with phasing out injectables use. The replacement sequence of drugs for DR-TB have also been updated. Updated definitions for pre-XDR, XDR, culture conversion and default have also been added. These guidelines are a paradigm shift which will make treating DR-TB easier and more efficient especially during the ongoing COVID-19 pandemic crisis. Tuberculosis Association of India. Published by Elsevier B.V. 2022-07 2021-08-16 /pmc/articles/PMC8366038/ /pubmed/35760475 http://dx.doi.org/10.1016/j.ijtb.2021.08.013 Text en © 2021 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Viewpoint Gupta, Mansi Ish, Pranav Malhotra, Nipun Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis |
title | Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis |
title_full | Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis |
title_fullStr | Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis |
title_full_unstemmed | Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis |
title_short | Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis |
title_sort | recent updates in diagnosis and management of drug-resistant tuberculosis in india: a paradigm shift and the way ahead during the covid-19 crisis |
topic | Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366038/ https://www.ncbi.nlm.nih.gov/pubmed/35760475 http://dx.doi.org/10.1016/j.ijtb.2021.08.013 |
work_keys_str_mv | AT guptamansi recentupdatesindiagnosisandmanagementofdrugresistanttuberculosisinindiaaparadigmshiftandthewayaheadduringthecovid19crisis AT ishpranav recentupdatesindiagnosisandmanagementofdrugresistanttuberculosisinindiaaparadigmshiftandthewayaheadduringthecovid19crisis AT malhotranipun recentupdatesindiagnosisandmanagementofdrugresistanttuberculosisinindiaaparadigmshiftandthewayaheadduringthecovid19crisis |